GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?

Although the mainstay of glycaemic control in type 1 diabetes has been the replacement of insulin to address the secretory deficiency caused by destruction of β cells, supplementary glucose-lowering treatments such as metformin, amylin analogues, SGLT2 inhibitors, and GLP-1 receptor agonists have been tested in clinical trials hoping for improved efficacy and safety. 1 Frandsen CS Dejgaard TF Madsbad S Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol. 2016; 4: 766-780 Summary Full Text Full Text PDF PubMed Scopus (62) Google Scholar Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trialShort-acting exenatide does not seem to have a future as a standard add-on treatment to insulin therapy in type 1 diabetes. Full-Text PDF